The 307th Hospital of Military Chinese People's Liberation Army Trials

The 307th Hospital of Military Chinese People's Liberation Army	Welcome, Profile Billing Logout

87 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

xu, jianmin

NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Recruiting

RoW

VIC, Bevacizumab Plus Chemotherapy

Fudan University

Colorectal Cancer

08/22

12/22

PIDUC, NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis

Not yet recruiting

RoW

Trans arterial chemoembolization with Irinotecan Drug-eluting Beads, Irinotecan Drug-eluting Beads

Fudan University

Colorectal Cancer, Liver Metastases

12/22

06/23

NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Recruiting

508

RoW

mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

03/25

09/27

BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Recruiting

308

RoW

mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab

Fudan University

Colorectal Carcinoma, Liver Metastases

03/24

03/26

NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Not yet recruiting

250

RoW

mFOLFOX6 + Cetuximab, mFOLFOX 6

Fudan University

Colorectal Cancer, Liver Metastases

07/26

NCT05086614: Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting

2500

RoW

Thymosin Alpha1, Thymalfasin

Fudan University

Stage II Colorectal Cancer, Stage III Colorectal Cancer

03/27

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Recruiting

RoW

Cadonilimab + bevacizumab + FOLFOX

Fudan University

Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab

12/25

12/26

SHR-1701-II-213, NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting

RoW

SHR-1701；Capecitabine；Oxaliplatin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Locally Advanced Rectal Cancer

07/24

10/26

China AZUR-1, NCT06640049: A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Recruiting

RoW

Dostarlimab, GSK4057190A, TSR-042

GlaxoSmithKline

Neoplasms, Rectal

12/28

03/31

NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Recruiting

116

RoW

Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy

Fudan University

Metastatic Colorectal Cancer

09/25

NCT06221423: Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Recruiting

N/A

RoW

Fruquintinib Combined With TAS-102

Fudan University

Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma

05/24

NCT06202417: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Completed

N/A

520

RoW

Fruquintinib, PD1 antibodies, chemotherapy drugs

Fudan University

Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer

06/22

12/23

NCT06027775: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases

Completed

N/A

198

Targeted agent

Fudan University

Colorectal Cancer Metastatic

01/23

NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

Completed

N/A

307

RoW

Deep radiomics-based fusion model, deep learning model

Fudan University

The Patients With CRLM Who Benefit More From Bevacizumab

01/23

REAL, NCT02817126: Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer

Active, not recruiting

N/A

1240

RoW

Robot-assisted resection, Laparoscopic resection

Fudan University

Rectal Carcinoma

12/23

DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

Not yet recruiting

N/A

RoW

DEBIRI Combined With Chemotherapy and Bevacizumab

Fudan University

Colorectal Neoplasms

01/25

05/25

NCT05873972: Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Not yet recruiting

N/A

100

RoW

Cetuximab

Fudan University

Colorectal Cancer Liver Metastases

06/24

12/24

NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Not yet recruiting

N/A

302

RoW

Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

07/25

07/28

NCT05881746: Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

Not yet recruiting

N/A

176

RoW

anatomical liver resection, nonanatomical liver resection

Fudan University

Colorectal Carcinoma, Liver Metastases

07/26

07/28

METHOD-3, NCT05638243: Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program

Recruiting

N/A

10000

RoW

Fudan University

Colorectal Cancer, Colorectal Neoplasms

02/25

09/25

Jiang, Zefei

NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting

408

RoW

HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Breast Cancer

11/21

TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting

287

RoW

TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive,HER2-negative in Advanced Breast Cancer

01/24

12/25

Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting

224

RoW

DB-1303/BNT323, T-DM1

DualityBio Inc., BioNTech SE

HER2-positive Breast Cancer

02/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting

560

RoW

Capivasertib, AZD5363, Fulvestrant

AstraZeneca

Breast Cancer

04/26

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting

1/2

146

RoW

HRS-8080; Dalpiciclib Isethionate Tablets

Shandong Suncadia Medicine Co., Ltd.

Unresectable or Metastatic Breast Cancer

10/25

12/25

NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting

162

SSGJ-705

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Receptor, ErbB-2

12/23

06/24

QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting

RoW

QLS12004

Qilu Pharmaceutical Co., Ltd.

Advanced Solid Tumor

05/24

05/25

Xu, Jianming

KL140-III-01, NCT03426371: Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Recruiting

570

RoW

KL-140, Placebo

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Metastatic Colorectal Cancer

12/20

12/23

NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated

RoW

Icaritin, Sorafenib Tosylate Tablets

Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital

Hepatocellular Carcinoma (HCC)

02/22

NCT04342910: Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting

550

RoW

camrelizumab, SHR-1210, Apatinib Mesylate, Paclitaxel, Irinotecan

Jiangsu HengRui Medicine Co., Ltd.

Gastric Cancer

04/22

09/22

KL140-Ⅲ-02-CTP, NCT04835142: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Completed

688

RoW

Double blind control period A140, KL-140, Open single period A140

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Metastatic Colorectal Cancer

03/23

01/24

NCT04415853: Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Recruiting

416

RoW

Lerotinib, Z650, Irinotecan/Tegafur, Irinotecan Hydrochloride Injection/Tegafur Gimeracil Oteracil Potassium Capsule

Sunshine Lake Pharma Co., Ltd.

Esophageal Cancer

08/23

11/23

NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Terminated

185

RoW

Famitinib capsules, Sunitinib Capsules, Sutent

Jiangsu HengRui Medicine Co., Ltd.

Gastrointestinal Stromal Tumors

03/22

NCT06432296: Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Recruiting

270

RoW

M701, paracentesis

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites

08/25

11/25

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruiting

196

RoW

Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide

Sinotau Pharmaceutical Group

Neuroendocrine Tumors

12/24

12/28

SCT-I10A-C301, NCT04560894: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruiting

2/3

405

RoW

SCT-I10A, SCT510, Sorafenib 200mg

Sinocelltech Ltd.

Hepatocellular Carcinoma

04/24

09/24

NCT05427383: KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Recruiting

2/3

286

RoW

KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection

Shanghai JMT-Bio Inc.

Stomach Cancer

11/25

11/26

NCT06266091: Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Active, not recruiting

RoW

M701, paracentesis

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites

03/24

12/24

NCT04466254: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Recruiting

RoW

CPGJ602, cetuximab

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastatic Colorectal Cancer

12/21

03/22

NCT06158516: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Not yet recruiting

100

RoW

Surufatinib, Placebo

Changhai Hospital

Pancreatic Neuroendocrine Tumor

11/26

NCT06247956: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Recruiting

240

RoW

SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

06/25

12/25

AB-106-C205, NCT04617054: Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

Recruiting

RoW

AB-106

AnHeart Therapeutics Inc.

Solid Tumor

04/24

12/26

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

NCT06505395: A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting

RoW

SYHX2008 injection, Sandostatin LAR@

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Gastrointestinal Neuroendocrine Pancreatic Tumor

08/27

08/28

NCT04353375: Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Recruiting

128

RoW

HMPL-453

Hutchmed

Advanced Intrahepatic Cholangiocarcinoma

06/25

12/25

NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting

RoW

PM8002, FOLFIRI

Biotheus Inc.

Neuroendocrine Neoplasm

01/27

01/28

NCT06237400: A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Recruiting

1/2

110

RoW

ZG19018

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

KRAS G12C Mutant Advanced Solid Tumors

05/25

NCT03888092: Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Completed

1/2

RoW

Z650, Larotinib

Sunshine Lake Pharma Co., Ltd.

Esophageal Squamous Cell Carcinoma

12/22

AK109-102, NCT05142423: A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Recruiting

1/2

198

RoW

AK109+AK104

Akeso

Advanced Solid Tumor

12/24

NCT04699643: FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

	First patient dosed in combination with Keytruda in HCC
	Aug 2020 - Aug 2020: First patient dosed in combination with Keytruda in HCC

Recruiting

1/2

RoW

EVER4010001, Pembrolizumab

EverNov Medicines (Zhuhai Hengqin) Co., Ltd, Medidata Solutions

Advanced Solid Tumors

06/23

NCT06237413: A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Recruiting

1/2

110

RoW

ZG2001 Tosilate Tablets, ZG2001

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Solid Tumor, KRAS Mutation-Related Tumors

02/26

ZG005-004, NCT06372626: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Recruiting

1/2

RoW

ZG005, Etoposide, Cisplatin, Placebo

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Neuroendocrine Carcinoma

07/26

08/26

NCT06440057: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Recruiting

1/2

RoW

ZG006

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Neuroendocrine Carcinoma

05/26

07/26

NCT05173142: HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Recruiting

1/2

141

RoW

HMPL-453, gemcitabine and cisplatin, toripalimab, Docetaxel

Hutchison Medipharma Limited

Solid Tumor

09/24

08/25

NCT05805956: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Recruiting

1/2

105

RoW

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma

10/24

NCT05584800: Study of ZGGS18 in Patients With Advanced Solid Tumors

Recruiting

1/2

222

RoW

ZGGS18 for Injection

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Advanced Solid Tumor

11/25

NCT02489201: A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Terminated

RoW

donafenib tosilate tablets, CM4307

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oesophageal Cancer

10/20

NCT04501744: A Study of M701 (EpCAM and CD3) in Malignant Ascites

Recruiting

RoW

Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701, Cohort 4 of M701, Cohort 5 of M701, Cohort 6 of M701, Cohort 7 of M701

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites, Cancer

01/21

06/21

NCT05123209: Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Recruiting

RoW

IM83 CAR-T cells, The second-line treatment of liver cancer

Beijing Immunochina Medical Science & Technology Co., Ltd.

Liver Cancer

08/23

MIZAR, NCT05417750: A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors

Recruiting

RoW

TIL therapy

Shanghai Juncell Therapeutics

Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy, Efficacy, Adverse Drug Event

11/25

04/26

NCT04998422: A Study of HG381 Administered to Patients With Advanced Solid Tumors

Recruiting

RoW

HG381, HG381 for Injection

HitGen Inc.

Advanced Solid Tumor

06/24

12/24

NCT04965077: Treatment of Advanced and Metastatic Solid Tumors With MIL97

Recruiting

RoW

Recombinant Humanized Monoclonal Antibody MIL97 for Injection

Beijing Mabworks Biotech Co., Ltd.

Advanced or Metastatic Solid Tumor

12/25

12/26

NCT05275062: Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Recruiting

RoW

IM92 CAR-T cells

Beijing Immunochina Medical Science & Technology Co., Ltd.

Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer

03/24

05/24

NCT05382377: NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Recruiting

RoW

KD-025

jianming xu, KAEDI

CRC, Solid Tumor

05/24

05/26

NCT05583201: NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Recruiting

RoW

KD-496

jianming xu, KAEDI

Gastric Cancer, Pancreatic Cancer, Solid Tumor

06/24

06/26

CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting

556

RoW

IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC

Innovent Biologics (Suzhou) Co. Ltd.

Advanced Malignancies

06/25

12/26

NCT05352542: GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Terminated

RoW

GPC3 Targeting CART Cells

jianming xu, Nanjing Legend Biotech Co.

Advanced Hepatocellular Carcinoma

07/24

NCT05427396: A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Recruiting

198

RoW

JS004, Toripalimab Injection

Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

08/24

08/25

NCT05191667: AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Suspended

RoW

AN0025, Paclitaxel, Carboplatin, Radiotherapy

Adlai Nortye Biopharma Co., Ltd.

Esophageal Cancer

12/25

FLIGHT, NCT05522309: FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors

Recruiting

RoW

ET0111

Etern BioPharma (Shanghai) Co., Ltd

Advanced Solid Tumor

12/24

05/25

CSG-1906-101, NCT05857332: SG1906 for CLDN18.2-Positive Solid Tumors

Recruiting

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

SHR-A2009-I-102, NCT05394818: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Completed

RoW

SHR-A2009

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Solid Tumor

04/24

NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting

RoW

IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection

Suzhou Immunofoco Biotechnology Co., Ltd

Advanced Digestive System Tumor

12/25

NCT05192460: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

Recruiting

N/A

RoW

neoantigen tumor vaccine with or without PD-1/L1, PGV002 mRNA Vaccine

jianming xu, NeoCura

Gastric Cancer, Esophageal Cancer, Liver Cancer

12/24

06/25

NCT05940181: A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Recruiting

N/A

RoW

XH001+ sintilimab

jianming xu, NeoCura

Solid Tumor

05/25

12/25

Liu, Xiaoqing

NCT06331156 / 2022-000708-36: A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants

Completed

400

RoW

HRV PCV-free, Rotarix PCV-free, IPV, Beijing Biological Products Institute Co.,Ltd.'s Inactivated Poliomyelitis Vaccine Made From Sabin Strains (Vero Cells)

GlaxoSmithKline, GlaxoSmithKline Biologicals SA

Gastroenteritis

10/24

NCT03108794: A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Recruiting

N/A

200000

RoW

Beijing Friendship Hospital, Beijing YouAn Hospital, The First Hospital of Jilin University, Henan Provincial People's Hospital, Beijing Ditan Hospital, First Affiliated Hospital of Xinjiang Medical University, LanZhou University, The Second Affiliated Hospital of Chongqing Medical University, West China Hospital, Taiyuan No.3 Hospital, Hebei Medical University Third Hospital, Shengjing Hospital, Tianjin Third Central Hospital, Peking University First Hospital, Peking Union Medical College Hospital, The Affiliated Hospital Of Southwest Medical University, Shanghai Public Health Clinical Center, Ruijin Hospital, First Affiliated Hospital Xi'an Jiaotong University, Xiangya Hospital of Central South University, Beijing Tiantan Hospital, Wuhan University, The First Affiliated Hospital of Kunming Medical College, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Hospital of Yanbian University, First Affiliated Hospital of Chongqing Medical University, The Fouth Hospital of Qinghai province, Weifang Medical University, Hunan Provincial People's Hospital, The Second Hospital of Hebei Medical University, Xixi Hospital of Hangzhou, General Hospital of Ningxia Medical University, Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Peking University People's Hospital, Nanfang Hospital of Southern Medical University, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Hainan General Hospital, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Fifth Hospital of Shijiazhuang City, Yan'an University Affiliated Hospital, Infectious Disease Hospital of Wuhai, Logistics University of Chinese People's Armed Police Forces, People's Hospital of Changji Hui Autonomous Prefecture，Xinjiang

Chronic Hepatitis B

12/22

12/25

Duan, Lian

No trials found

Hu, Jinchao

No trials found

Lian, Lian

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

xu, jianmin

NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Recruiting

RoW

VIC, Bevacizumab Plus Chemotherapy

Fudan University

Colorectal Cancer

08/22

12/22

PIDUC, NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis

Not yet recruiting

RoW

Trans arterial chemoembolization with Irinotecan Drug-eluting Beads, Irinotecan Drug-eluting Beads

Fudan University

Colorectal Cancer, Liver Metastases

12/22

06/23

NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Recruiting

508

RoW

mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

03/25

09/27

BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Recruiting

308

RoW

mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab

Fudan University

Colorectal Carcinoma, Liver Metastases

03/24

03/26

NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Not yet recruiting

250

RoW

mFOLFOX6 + Cetuximab, mFOLFOX 6

Fudan University

Colorectal Cancer, Liver Metastases

07/26

NCT05086614: Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting

2500

RoW

Thymosin Alpha1, Thymalfasin

Fudan University

Stage II Colorectal Cancer, Stage III Colorectal Cancer

03/27

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Recruiting

RoW

Cadonilimab + bevacizumab + FOLFOX

Fudan University

Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab

12/25

12/26

SHR-1701-II-213, NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting

RoW

SHR-1701；Capecitabine；Oxaliplatin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Locally Advanced Rectal Cancer

07/24

10/26

China AZUR-1, NCT06640049: A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Recruiting

RoW

Dostarlimab, GSK4057190A, TSR-042

GlaxoSmithKline

Neoplasms, Rectal

12/28

03/31

NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Recruiting

116

RoW

Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy

Fudan University

Metastatic Colorectal Cancer

09/25

NCT06221423: Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Recruiting

N/A

RoW

Fruquintinib Combined With TAS-102

Fudan University

Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma

05/24

NCT06202417: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Completed

N/A

520

RoW

Fruquintinib, PD1 antibodies, chemotherapy drugs

Fudan University

Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer

06/22

12/23

NCT06027775: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases

Completed

N/A

198

Targeted agent

Fudan University

Colorectal Cancer Metastatic

01/23

NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

Completed

N/A

307

RoW

Deep radiomics-based fusion model, deep learning model

Fudan University

The Patients With CRLM Who Benefit More From Bevacizumab

01/23

REAL, NCT02817126: Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer

Active, not recruiting

N/A

1240

RoW

Robot-assisted resection, Laparoscopic resection

Fudan University

Rectal Carcinoma

12/23

DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

Not yet recruiting

N/A

RoW

DEBIRI Combined With Chemotherapy and Bevacizumab

Fudan University

Colorectal Neoplasms

01/25

05/25

NCT05873972: Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Not yet recruiting

N/A

100

RoW

Cetuximab

Fudan University

Colorectal Cancer Liver Metastases

06/24

12/24

NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Not yet recruiting

N/A

302

RoW

Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

07/25

07/28

NCT05881746: Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

Not yet recruiting

N/A

176

RoW

anatomical liver resection, nonanatomical liver resection

Fudan University

Colorectal Carcinoma, Liver Metastases

07/26

07/28

Recruiting

N/A

10000

RoW

Fudan University

Colorectal Cancer, Colorectal Neoplasms

02/25

09/25

Jiang, Zefei

NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting

408

RoW

HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel

Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Breast Cancer

11/21

TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting

287

RoW

TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive,HER2-negative in Advanced Breast Cancer

01/24

12/25

Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting

224

RoW

DB-1303/BNT323, T-DM1

DualityBio Inc., BioNTech SE

HER2-positive Breast Cancer

02/26

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting

560

RoW

Capivasertib, AZD5363, Fulvestrant

AstraZeneca

Breast Cancer

04/26

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting

414

RoW

Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine

Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Triple Negative Breast Cancer, Nab-paclitaxel

06/22

09/22

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting

1/2

146

RoW

HRS-8080; Dalpiciclib Isethionate Tablets

Shandong Suncadia Medicine Co., Ltd.

Unresectable or Metastatic Breast Cancer

10/25

12/25

NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting

162

SSGJ-705

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Receptor, ErbB-2

12/23

06/24

QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting

RoW

QLS12004

Qilu Pharmaceutical Co., Ltd.

Advanced Solid Tumor

05/24

05/25

Xu, Jianming

KL140-III-01, NCT03426371: Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Recruiting

570

RoW

KL-140, Placebo

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Metastatic Colorectal Cancer

12/20

12/23

NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated

RoW

Icaritin, Sorafenib Tosylate Tablets

Hepatocellular Carcinoma (HCC)

02/22

NCT04342910: Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting

550

RoW

camrelizumab, SHR-1210, Apatinib Mesylate, Paclitaxel, Irinotecan

Jiangsu HengRui Medicine Co., Ltd.

Gastric Cancer

04/22

09/22

KL140-Ⅲ-02-CTP, NCT04835142: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Completed

688

RoW

Double blind control period A140, KL-140, Open single period A140

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Metastatic Colorectal Cancer

03/23

01/24

NCT04415853: Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Recruiting

416

RoW

Lerotinib, Z650, Irinotecan/Tegafur, Irinotecan Hydrochloride Injection/Tegafur Gimeracil Oteracil Potassium Capsule

Sunshine Lake Pharma Co., Ltd.

Esophageal Cancer

08/23

11/23

NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Terminated

185

RoW

Famitinib capsules, Sunitinib Capsules, Sutent

Jiangsu HengRui Medicine Co., Ltd.

Gastrointestinal Stromal Tumors

03/22

NCT06432296: Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Recruiting

270

RoW

M701, paracentesis

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites

08/25

11/25

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruiting

196

RoW

Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide

Sinotau Pharmaceutical Group

Neuroendocrine Tumors

12/24

12/28

SCT-I10A-C301, NCT04560894: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruiting

2/3

405

RoW

SCT-I10A, SCT510, Sorafenib 200mg

Sinocelltech Ltd.

Hepatocellular Carcinoma

04/24

09/24

NCT05427383: KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Recruiting

2/3

286

RoW

KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection

Shanghai JMT-Bio Inc.

Stomach Cancer

11/25

11/26

NCT06266091: Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Active, not recruiting

RoW

M701, paracentesis

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites

03/24

12/24

NCT04466254: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Recruiting

RoW

CPGJ602, cetuximab

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastatic Colorectal Cancer

12/21

03/22

NCT06158516: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Not yet recruiting

100

RoW

Surufatinib, Placebo

Changhai Hospital

Pancreatic Neuroendocrine Tumor

11/26

NCT06247956: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Recruiting

240

RoW

SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

06/25

12/25

AB-106-C205, NCT04617054: Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

Recruiting

RoW

AB-106

AnHeart Therapeutics Inc.

Solid Tumor

04/24

12/26

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

NCT06505395: A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting

RoW

SYHX2008 injection, Sandostatin LAR@

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Gastrointestinal Neuroendocrine Pancreatic Tumor

08/27

08/28

NCT04353375: Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Recruiting

128

RoW

HMPL-453

Hutchmed

Advanced Intrahepatic Cholangiocarcinoma

06/25

12/25

NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting

RoW

PM8002, FOLFIRI

Biotheus Inc.

Neuroendocrine Neoplasm

01/27

01/28

NCT06237400: A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Recruiting

1/2

110

RoW

ZG19018

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

KRAS G12C Mutant Advanced Solid Tumors

05/25

NCT03888092: Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Completed

1/2

RoW

Z650, Larotinib

Sunshine Lake Pharma Co., Ltd.

Esophageal Squamous Cell Carcinoma

12/22

AK109-102, NCT05142423: A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Recruiting

1/2

198

RoW

AK109+AK104

Akeso

Advanced Solid Tumor

12/24

NCT04699643: FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

	First patient dosed in combination with Keytruda in HCC
	Aug 2020 - Aug 2020: First patient dosed in combination with Keytruda in HCC

Recruiting

1/2

RoW

EVER4010001, Pembrolizumab

EverNov Medicines (Zhuhai Hengqin) Co., Ltd, Medidata Solutions

Advanced Solid Tumors

06/23

NCT06237413: A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Recruiting

1/2

110

RoW

ZG2001 Tosilate Tablets, ZG2001

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Solid Tumor, KRAS Mutation-Related Tumors

02/26

ZG005-004, NCT06372626: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Recruiting

1/2

RoW

ZG005, Etoposide, Cisplatin, Placebo

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Neuroendocrine Carcinoma

07/26

08/26

Recruiting

1/2

RoW

ZG006

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Neuroendocrine Carcinoma

05/26

07/26

NCT05173142: HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Recruiting

1/2

141

RoW

HMPL-453, gemcitabine and cisplatin, toripalimab, Docetaxel

Hutchison Medipharma Limited

Solid Tumor

09/24

08/25

NCT05805956: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Recruiting

1/2

105

RoW

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma

10/24

NCT05584800: Study of ZGGS18 in Patients With Advanced Solid Tumors

Recruiting

1/2

222

RoW

ZGGS18 for Injection

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Advanced Solid Tumor

11/25

NCT02489201: A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Terminated

RoW

donafenib tosilate tablets, CM4307

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oesophageal Cancer

10/20

NCT04501744: A Study of M701 (EpCAM and CD3) in Malignant Ascites

Recruiting

RoW

Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701, Cohort 4 of M701, Cohort 5 of M701, Cohort 6 of M701, Cohort 7 of M701

Wuhan YZY Biopharma Co., Ltd.

Malignant Ascites, Cancer

01/21

06/21

NCT05123209: Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Recruiting

RoW

IM83 CAR-T cells, The second-line treatment of liver cancer

Beijing Immunochina Medical Science & Technology Co., Ltd.

Liver Cancer

08/23

MIZAR, NCT05417750: A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors

Recruiting

RoW

TIL therapy

Shanghai Juncell Therapeutics

Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy, Efficacy, Adverse Drug Event

11/25

04/26

NCT04998422: A Study of HG381 Administered to Patients With Advanced Solid Tumors

Recruiting

RoW

HG381, HG381 for Injection

HitGen Inc.

Advanced Solid Tumor

06/24

12/24

NCT04965077: Treatment of Advanced and Metastatic Solid Tumors With MIL97

Recruiting

RoW

Recombinant Humanized Monoclonal Antibody MIL97 for Injection

Beijing Mabworks Biotech Co., Ltd.

Advanced or Metastatic Solid Tumor

12/25

12/26

NCT05275062: Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Recruiting

RoW

IM92 CAR-T cells

Beijing Immunochina Medical Science & Technology Co., Ltd.

Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer

03/24

05/24

NCT05382377: NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Recruiting

RoW

KD-025

jianming xu, KAEDI

CRC, Solid Tumor

05/24

05/26

NCT05583201: NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Recruiting

RoW

KD-496

jianming xu, KAEDI

Gastric Cancer, Pancreatic Cancer, Solid Tumor

06/24

06/26

CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting

556

RoW

IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC

Innovent Biologics (Suzhou) Co. Ltd.

Advanced Malignancies

06/25

12/26

NCT05352542: GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Terminated

RoW

GPC3 Targeting CART Cells

jianming xu, Nanjing Legend Biotech Co.

Advanced Hepatocellular Carcinoma

07/24

NCT05427396: A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Recruiting

198

RoW

JS004, Toripalimab Injection

Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

08/24

08/25

NCT05191667: AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Suspended

RoW

AN0025, Paclitaxel, Carboplatin, Radiotherapy

Adlai Nortye Biopharma Co., Ltd.

Esophageal Cancer

12/25

FLIGHT, NCT05522309: FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors

Recruiting

RoW

ET0111

Etern BioPharma (Shanghai) Co., Ltd

Advanced Solid Tumor

12/24

05/25

CSG-1906-101, NCT05857332: SG1906 for CLDN18.2-Positive Solid Tumors

Recruiting

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

SHR-A2009-I-102, NCT05394818: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Completed

RoW

SHR-A2009

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Solid Tumor

04/24

NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting

RoW

IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection

Suzhou Immunofoco Biotechnology Co., Ltd

Advanced Digestive System Tumor

12/25

NCT05192460: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

Recruiting

N/A

RoW

neoantigen tumor vaccine with or without PD-1/L1, PGV002 mRNA Vaccine

jianming xu, NeoCura

Gastric Cancer, Esophageal Cancer, Liver Cancer

12/24

06/25

NCT05940181: A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Recruiting

N/A

RoW

XH001+ sintilimab

jianming xu, NeoCura

Solid Tumor

05/25

12/25

Liu, Xiaoqing

Completed

400

RoW

HRV PCV-free, Rotarix PCV-free, IPV, Beijing Biological Products Institute Co.,Ltd.'s Inactivated Poliomyelitis Vaccine Made From Sabin Strains (Vero Cells)

GlaxoSmithKline, GlaxoSmithKline Biologicals SA

Gastroenteritis

10/24

NCT03108794: A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Recruiting

N/A

200000

RoW

Chronic Hepatitis B

12/22

12/25

Duan, Lian

No trials found

Hu, Jinchao

No trials found

Lian, Lian

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites